Advanced Nursing Practice and Science Division, College of Nursing, University of Arizona, Tucson, AZ; University of Arizona Cancer Center, Tucson, AZ; Division of Oncological Sciences, Knight Cancer Institute, School of Medicine, Oregon Health & Science University, Portland OR.
APDM, a Clario Inc Company, Portland, OR.
Arch Phys Med Rehabil. 2024 Jun;105(6):1106-1115. doi: 10.1016/j.apmr.2024.01.019. Epub 2024 Feb 12.
This study aimed to characterize mobility patterns using wearable inertial sensors and serial assessment across autologous hematopoietic cell transplant (autoHCT) and investigate the relation between mobility and perceived function in patients with hematologic cancer.
Prospective longitudinal study.
Hospital adult transplant clinic followed by discharge.
78 patients with hematological cancer receiving autoHCT.
Mobility was measured across 3 clinical phases (pretransplant, pre-engraftment, and post-engraftment) in using inertial sensors worn during prescribed performance tests in the hospital. Perceived function was assessed using validated provider-reported (Eastern Cooperative Oncology Group [ECOG] Performance Status Scale) and patient-reported [European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]) measures. Trajectories of 5 selected mobility characteristics (turn duration, gait speed, stride time variability, double support time, and heel strike angle) across the clinical phases were also evaluated using piecewise linear mixed-effects models.
Using Principal Components Analysis, 4 mobility patterns were identified pretransplant: Gait Limitation, Sagittal Sway, Coronal Sway, and Balance Control. Gait Limitation measured pretransplant was significantly inversely associated with perceived function reported by the provider- (β = -0.11; 95% CI: -0.19, -0.02) and patient- (β = -4.85; 95% CI: -7.72, -1.99) post-engraftment in age-adjusted linear regression models. Mobility characteristics demonstrated immediate declines early pre-engraftment with stabilization by late pre-engraftment.
Patients with hematological cancer experiencing gait limitations pretransplant are likely to have worse perceived function post-engraftment. Mobility declines in early phases post-transplant and may not fully recover, indicating an opportunity for timely rehabilitation referrals. Wearable inertial sensors can be used to identify early mobility problems and patients who may be at risk for future functional decline who may be candidates for early physical rehabilitation.
本研究旨在使用可穿戴惯性传感器对自体造血细胞移植(autoHCT)期间的移动模式进行特征描述,并探讨血液恶性肿瘤患者移动能力与感知功能之间的关系。
前瞻性纵向研究。
医院成人移植诊所,随后出院。
78 例接受 autoHCT 的血液恶性肿瘤患者。
使用惯性传感器在医院规定的性能测试期间佩戴,在 3 个临床阶段(移植前、植入前和植入后)测量移动能力。感知功能使用经过验证的提供者报告(东部合作肿瘤学组[ECOG]表现状态量表)和患者报告[欧洲癌症研究与治疗组织生活质量问卷[EORTC QLQ-C30])措施进行评估。还使用分段线性混合效应模型评估 5 个选定移动特征(转弯持续时间、步行速度、步时变异性、双支撑时间和脚跟触地角度)在临床阶段的轨迹。
使用主成分分析,在移植前识别出 4 种移动模式:步态受限、矢状面摇晃、冠状面摇晃和平衡控制。在年龄调整的线性回归模型中,移植前测量的步态受限与植入后提供者报告的感知功能(β=-0.11;95%CI:-0.19,-0.02)和患者报告的感知功能(β=-4.85;95%CI:-7.72,-1.99)呈显著负相关。在植入前早期,移动特征立即下降,在植入前晚期稳定。
移植前出现步态受限的血液恶性肿瘤患者植入后感知功能可能更差。移植后早期移动能力下降,可能无法完全恢复,表明有机会及时进行康复转诊。可穿戴惯性传感器可用于识别早期移动问题和可能有未来功能下降风险的患者,这些患者可能是早期物理康复的候选者。